Sinta Jimenez, host of The Pro-Life American and Director of Digital Strategy at SBA Pro-Life America, sits down with her colleague Abigail Balmert, Director of Legal Affairs and Policy Counsel at SBA, to discuss the new FDA update on abortion drugs released in October 2026.
Abigail describes a five-page court-ordered status report on the safety of mifepristone. Data collection is expected to wrap up in mid-December, with a final report no later than March 2027. She notes that then-Commissioner Makary said the study was underway in January 2025, and that a deadline told to a judge is more reliable than one given only to the public, though an extension would not be a surprise.
They discuss pressure to restore in-person dispensing after the FDA conceded that earlier data was not sufficient to remove that requirement, the risks of remote dispensing for ectopic pregnancy and gestational age, and reports of women who only filled out an online form. Sinta compares the lack of oversight to the opioid crisis. Abigail says SBA president Marjorie Dannenfelser has urged the administration to restore in-person dispensing immediately through a consent decree in the federal case against Louisiana, and that the Department of Justice also has enforcement pathways independent of the FDA study.
Abigail then explains a Supreme Court filing in which Louisiana, Alabama, and Arkansas are suing New York, California, and Massachusetts over shield laws, arguing violations of the full faith and credit clause, equal sovereignty among the states, the dormant commerce clause, and the federal common law of public nuisance. A second lawsuit in the Western District of Louisiana names individuals and web-based entities prescribing and shipping abortion drugs. Sinta describes packaging from a Memphis, Tennessee pregnancy center visitor that looked like a greeting card, with little baggies, a mismatched return address, and a local library listed.
Asked what Congress can do, Abigail points to Senator Banks signaling that the FDA is being watched, and to Congress's power over the FDCA. On Marjorie's description of the update as fool's gold, Abigail says a solid study must be rigorous, rooted in science, and not rely on low voluntary adverse-event reporting. She cites researcher Studnicki, who used insurance records to find women who took the drugs and then presented within 30 days with miscarriage-related coding. Abigail closes by saying common ground should be proper regulation of medicine, protecting women from ectopic rupture, wrong gestational age, and abortion drugs used against women who want the baby.